Cm Management, LLC Nektar Therapeutics Transaction History

Cm Management, LLC

  • $107 Million
  • Q4 2024

A detailed history of Cm Management, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Cm Management, LLC holds 750,000 shares of NKTR stock, worth $795,000. This represents 0.65% of its overall portfolio holdings.

Number of Shares
750,000
Previous 750,000 -0.0%
Holding current value
$795,000
Previous $975,000 28.51%
% of portfolio
0.65%
Previous 0.82%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024
SELL
$0.9 - $1.83 $170,862 - $347,420
-189,847 Reduced 20.2%
750,000 $930,000
Q4 2023

Feb 12, 2024
BUY
$0.42 - $0.57 $58,735 - $79,712
139,847 Added 17.48%
939,847 $526,000
Q3 2023

Nov 07, 2023
BUY
$0.51 - $1.05 $25,500 - $52,500
50,000 Added 6.67%
800,000 $480,000
Q2 2023

Aug 04, 2023
BUY
$0.53 - $1.03 $185,500 - $360,500
350,000 Added 87.5%
750,000 $431,000
Q1 2023

May 08, 2023
BUY
$0.64 - $3.15 $176,000 - $866,250
275,000 Added 220.0%
400,000 $281,000
Q4 2022

Feb 09, 2023
BUY
$2.03 - $4.28 $152,249 - $321,000
75,000 Added 150.0%
125,000 $283,000
Q3 2022

Nov 04, 2022
SELL
$3.04 - $5.14 $228,000 - $385,500
-75,000 Reduced 60.0%
50,000 $160,000
Q2 2022

Aug 08, 2022
BUY
$3.17 - $6.17 $158,500 - $308,500
50,000 Added 66.67%
125,000 $475,000
Q1 2022

May 09, 2022
BUY
$4.16 - $13.72 $208,000 - $686,000
50,000 Added 200.0%
75,000 $404,000
Q4 2021

Feb 02, 2022
SELL
$10.83 - $18.41 $270,750 - $460,250
-25,000 Reduced 50.0%
25,000 $338,000
Q1 2021

May 12, 2021
BUY
$16.56 - $25.46 $248,399 - $381,900
15,000 Added 42.86%
50,000 $1 Million
Q4 2020

Feb 04, 2021
BUY
$15.77 - $19.03 $551,950 - $666,050
35,000 New
35,000 $595,000

Others Institutions Holding NKTR

# of Institutions
152
Shares Held
131M
Call Options Held
92.7K
Put Options Held
4.9K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $199M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Cm Management, LLC Portfolio

Follow Cm Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cm Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cm Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email